NHS England is set to significantly enhance its bowel cancer screening programme by upgrading the sensitivity of the home-use faecal immunochemical test (FIT) kit. This crucial move, which experts anticipate will save hundreds of lives, aims for earlier cancer detection and the identification of high-risk pre-cancerous polyps. The core change involves lowering the threshold for a positive result, the level of blood detected that triggers a follow-up investigation, from 120 micrograms of blood per gram of stool to 80 micrograms per gram, aligning England's sensitivity with protocols already in use in Scotland and Wales.
This increased sensitivity is projected to yield substantial benefits for patient outcomes. The lower threshold is expected to lead to an 11% annual increase in early cancer detection, resulting in around 600 additional bowel cancer diagnoses each year at a more treatable stage. Furthermore, the change is anticipated to identify approximately 2,000 additional high-risk polyps annually. Removing these abnormal growths is a key preventative measure, significantly reducing the future risk of developing bowel cancer. Data from the National Bowel Cancer Audit confirms that early detection before symptoms appear is paramount for improved survival rates.
While the way patients use the FIT kit will remain the same, the greater sensitivity means that more people will be referred for follow-up tests, such as colonoscopies. NHS England forecasts a 35% increase in colonoscopy demand nationwide. Successful implementation requires close operational coordination between screening and diagnostic services to manage the increased demand and ensure timely follow-through. This new policy is a core component of England's National Cancer Plan, due on World Cancer Day (February 4th), which outlines a strategy to transform cancer care by 2035. Full implementation across England is anticipated by 2028.
The initiative has garnered strong support from patient advocacy groups. Bowel Cancer UK hailed the move as a “landmark step,” emphasising its role in reducing late diagnoses, improving survival, and lessening the intensity of treatment. Cancer Research UK echoed this, stressing that the lower threshold will detect more cancers when treatment is most likely to succeed. This improvement builds upon the recent success of extending eligible screening to everyone aged 50–74.
As Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, noted, the lower threshold provides a "better early-warning system." The critical message to the public remains unchanged: complete and return your bowel cancer screening kit when invited. The FIT kit is the most effective tool available for early diagnosis, offering the best chance of survival, less invasive treatment, and a better quality of life.
